A detailed history of Pro Share Advisors LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Pro Share Advisors LLC holds 33,734 shares of NKTR stock, worth $36,095. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,734
Holding current value
$36,095
% of portfolio
0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.11 - $1.48 $37,444 - $49,926
33,734 New
33,734 $43,000
Q3 2023

Nov 13, 2023

BUY
$0.51 - $1.05 $94 - $194
185 Added 1.51%
12,429 $7,000
Q2 2023

Aug 10, 2023

SELL
$0.53 - $1.03 $14,501 - $28,181
-27,361 Reduced 69.08%
12,244 $7,000
Q1 2023

May 11, 2023

SELL
$0.64 - $3.15 $3,052 - $15,025
-4,770 Reduced 10.75%
39,605 $27,000
Q4 2022

Feb 02, 2023

BUY
$2.03 - $4.28 $7,117 - $15,005
3,506 Added 8.58%
44,375 $100,000
Q3 2022

Nov 04, 2022

SELL
$3.04 - $5.14 $7,353 - $12,433
-2,419 Reduced 5.59%
40,869 $130,000
Q2 2022

Aug 01, 2022

BUY
$3.17 - $6.17 $42,918 - $83,535
13,539 Added 45.51%
43,288 $165,000
Q1 2022

May 10, 2022

SELL
$4.16 - $13.72 $27,688 - $91,320
-6,656 Reduced 18.28%
29,749 $161,000
Q4 2021

Feb 08, 2022

SELL
$10.83 - $18.41 $215,495 - $366,322
-19,898 Reduced 35.34%
36,405 $492,000
Q3 2021

Nov 12, 2021

BUY
$13.07 - $18.84 $41,641 - $60,024
3,186 Added 6.0%
56,303 $1.01 Million
Q2 2021

Aug 13, 2021

BUY
$16.52 - $20.4 $173,096 - $213,751
10,478 Added 24.57%
53,117 $911,000
Q1 2021

May 14, 2021

SELL
$16.56 - $25.46 $38,386 - $59,016
-2,318 Reduced 5.16%
42,639 $853,000
Q4 2020

Feb 09, 2021

BUY
$15.77 - $19.03 $15,170 - $18,306
962 Added 2.19%
44,957 $764,000
Q3 2020

Nov 13, 2020

BUY
$16.59 - $24.79 $15,063 - $22,509
908 Added 2.11%
43,995 $730,000
Q2 2020

Aug 03, 2020

BUY
$16.86 - $23.44 $154,555 - $214,874
9,167 Added 27.03%
43,087 $998,000
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $336,167 - $649,566
-23,232 Reduced 40.65%
33,920 $605,000
Q4 2019

Feb 12, 2020

SELL
$15.87 - $23.12 $233,955 - $340,835
-14,742 Reduced 20.51%
57,152 $1.23 Million
Q3 2019

Nov 12, 2019

SELL
$16.91 - $36.27 $30,353 - $65,104
-1,795 Reduced 2.44%
71,894 $1.31 Million
Q2 2019

Aug 13, 2019

SELL
$31.0 - $36.3 $723,385 - $847,060
-23,335 Reduced 24.05%
73,689 $2.62 Million
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $1.63 Million - $2.39 Million
-51,492 Reduced 34.67%
97,024 $3.26 Million
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $276,121 - $514,042
9,074 Added 6.51%
148,516 $4.88 Million
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $1.21 Million - $1.78 Million
26,030 Added 22.95%
139,442 $8.5 Million
Q2 2018

Aug 13, 2018

SELL
$46.25 - $104.45 $228,058 - $515,042
-4,931 Reduced 4.17%
113,412 $5.54 Million
Q1 2018

May 14, 2018

BUY
$57.4 - $108.44 $141,663 - $267,629
2,468 Added 2.13%
118,343 $12.6 Million
Q4 2017

Feb 14, 2018

BUY
$23.02 - $60.5 $250,089 - $657,272
10,864 Added 10.35%
115,875 $6.92 Million
Q3 2017

Nov 13, 2017

BUY
$17.79 - $24.0 $177,223 - $239,088
9,962 Added 10.48%
105,011 $2.52 Million
Q2 2017

Aug 11, 2017

BUY
N/A
95,049
95,049 $1.86 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.